- Home
- XCUR
XCUR
Exicure Inc.
as 10-30-2025 4:00pm EST
Exicure Inc is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. It operates in a single segment which is Biotechnology.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | CHICAGO |
| Market Cap: | 29.4M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 39.7K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.83 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.44 - $36.00 | Next Earning Date: | 11-10-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Exicure Inc. News
XCUR Breaking Stock News: Dive into XCUR Ticker-Specific Updates for Smart Investing
GlobeNewswire
25 days ago
Exicure Highlights Recent Achievements and Near-term Strategic Priorities
Business Wire
4 months ago
Exicure, Inc. Reports First Quarter 2025 Financial Results
Business Wire
5 months ago
Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q
Business Wire
6 months ago
Exicure Completes Patient Enrollment in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant
Business Wire
7 months ago
Exicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study of GPC-100 in Multiple Myeloma
Business Wire
7 months ago
Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML)
Business Wire
7 months ago
Exicure, Inc. Reports Full Year 2024 Financial Results
Business Wire
8 months ago
Exicure, Inc. (Nasdaq: XCUR) Announces Issuance of New Patent in Australia
Compare XCUR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "XCUR Exicure Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.